FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085698001> ?p ?o ?g. }

• W2085698001 endingPage "H1424" @default.
• W2085698001 startingPage "H1416" @default.
• W2085698001 abstract "Cyclooxygenase (COX)-2 is expressed in the heart in animal models of ischemic injury. Recent studies have suggested that COX-2 products are involved in inflammatory cell infiltration and fibroblast proliferation in the heart. Using a mouse model, we questioned whether 1). myocardial infarction (MI) in vivo induces COX-2 expression chronically, and 2). COX-2 inhibition reduces collagen content and improves cardiac function in mice with MI. MI was produced by ligation of the left anterior descending coronary artery in mice. Two days later, mice were treated with 3 mg/kg NS-398, a selective COX-2 inhibitor, or vehicle in drinking water for 2 wk. After the treatment period, mice were subjected to two-dimensional M-mode echocardiography to determine cardiac function. Hearts were then analyzed for determination of infarct size, interstitial collagen content, brain natriuretic peptide (BNP) mRNA, myocyte cross-sectional area, and immunohistochemical staining for transforming growth factor (TGF)-beta and COX-2. COX-2 protein, detected by immunohistochemistry, was increased in MI versus sham hearts. MI resulted in increased left ventricular systolic and diastolic dimension and decreased ejection fraction, fractional shortening, and cardiac output. NS-398 treatment partly reversed these detrimental changes. Myocyte cross-sectional area, a measure of hypertrophy, was decreased by 30% in the NS-398 versus vehicle group, but there was no effect on BNP mRNA. The interstitial collagen fraction increased from 5.4 +/- 0.4% in sham hearts to 10.4 +/- 0.9% in MI hearts and was decreased to 7.9 +/- 0.6% in NS-398-treated hearts. A second COX-2 inhibitor, rofecoxib (MK-0966), also decreased myocyte cross-sectional area and interstitial collagen fraction. TGF-beta, a key regulator of collagen synthesis, was increased in MI hearts. NS-398 treatment reduced TGF-beta immunostaining by 40%. NS-398 treatment had no effect on infarct size. These results suggest that COX-2 products contribute to cardiac remodeling and functional deficits after MI. Thus selected inhibition of COX-2 may be a therapeutic target for reducing myocyte damage after MI." @default.
• W2085698001 created "2016-06-24" @default.
• W2085698001 creator A5014414806 @default.
• W2085698001 creator A5022881840 @default.
• W2085698001 creator A5023692508 @default.
• W2085698001 creator A5027705218 @default.
• W2085698001 creator A5032990255 @default.
• W2085698001 date "2004-04-01" @default.
• W2085698001 modified "2023-10-15" @default.
• W2085698001 title "Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse" @default.
• W2085698001 cites W1584468150 @default.
• W2085698001 cites W1923159359 @default.
• W2085698001 cites W1968366982 @default.
• W2085698001 cites W1972613284 @default.
• W2085698001 cites W1976264663 @default.
• W2085698001 cites W1978765660 @default.
• W2085698001 cites W1986290379 @default.
• W2085698001 cites W1997364548 @default.
• W2085698001 cites W2010861717 @default.
• W2085698001 cites W2016874299 @default.
• W2085698001 cites W2018716226 @default.
• W2085698001 cites W2020563114 @default.
• W2085698001 cites W2021599930 @default.
• W2085698001 cites W2024233889 @default.
• W2085698001 cites W2047785103 @default.
• W2085698001 cites W2057367147 @default.
• W2085698001 cites W2058118671 @default.
• W2085698001 cites W2058755393 @default.
• W2085698001 cites W20603860 @default.
• W2085698001 cites W2061937172 @default.
• W2085698001 cites W2066349673 @default.
• W2085698001 cites W2070161415 @default.
• W2085698001 cites W2072772602 @default.
• W2085698001 cites W2082001748 @default.
• W2085698001 cites W2096198355 @default.
• W2085698001 cites W2098453740 @default.
• W2085698001 cites W2105788192 @default.
• W2085698001 cites W2113892902 @default.
• W2085698001 cites W2114014099 @default.
• W2085698001 cites W2116825773 @default.
• W2085698001 cites W2118195071 @default.
• W2085698001 cites W2125471714 @default.
• W2085698001 cites W2126853519 @default.
• W2085698001 cites W2129849271 @default.
• W2085698001 cites W2132722612 @default.
• W2085698001 cites W2135085072 @default.
• W2085698001 cites W2136718447 @default.
• W2085698001 cites W2146311014 @default.
• W2085698001 cites W2146936491 @default.
• W2085698001 cites W2149125209 @default.
• W2085698001 cites W2149233326 @default.
• W2085698001 cites W2156675756 @default.
• W2085698001 cites W2160277272 @default.
• W2085698001 cites W2167029659 @default.
• W2085698001 cites W2167977449 @default.
• W2085698001 cites W2169804106 @default.
• W2085698001 cites W2330496155 @default.
• W2085698001 cites W2396684049 @default.
• W2085698001 cites W2407751051 @default.
• W2085698001 doi "https://doi.org/10.1152/ajpheart.00136.2003" @default.
• W2085698001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14670812" @default.
• W2085698001 hasPublicationYear "2004" @default.
• W2085698001 type Work @default.
• W2085698001 sameAs 2085698001 @default.
• W2085698001 citedByCount "97" @default.
• W2085698001 countsByYear W20856980012012 @default.
• W2085698001 countsByYear W20856980012013 @default.
• W2085698001 countsByYear W20856980012014 @default.
• W2085698001 countsByYear W20856980012015 @default.
• W2085698001 countsByYear W20856980012016 @default.
• W2085698001 countsByYear W20856980012017 @default.
• W2085698001 countsByYear W20856980012018 @default.
• W2085698001 countsByYear W20856980012019 @default.
• W2085698001 countsByYear W20856980012020 @default.
• W2085698001 countsByYear W20856980012021 @default.
• W2085698001 countsByYear W20856980012022 @default.
• W2085698001 countsByYear W20856980012023 @default.
• W2085698001 crossrefType "journal-article" @default.
• W2085698001 hasAuthorship W2085698001A5014414806 @default.
• W2085698001 hasAuthorship W2085698001A5022881840 @default.
• W2085698001 hasAuthorship W2085698001A5023692508 @default.
• W2085698001 hasAuthorship W2085698001A5027705218 @default.
• W2085698001 hasAuthorship W2085698001A5032990255 @default.
• W2085698001 hasConcept C111566952 @default.
• W2085698001 hasConcept C126322002 @default.
• W2085698001 hasConcept C134018914 @default.
• W2085698001 hasConcept C150903083 @default.
• W2085698001 hasConcept C164705383 @default.
• W2085698001 hasConcept C181199279 @default.
• W2085698001 hasConcept C185592680 @default.
• W2085698001 hasConcept C204232928 @default.
• W2085698001 hasConcept C207001950 @default.
• W2085698001 hasConcept C207200792 @default.
• W2085698001 hasConcept C2775915353 @default.
• W2085698001 hasConcept C2778198053 @default.
• W2085698001 hasConcept C2779689624 @default.
• W2085698001 hasConcept C500558357 @default.
• W2085698001 hasConcept C55493867 @default.

• next